IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15

AUTHORS

Hai Bin He 1 , Xian Lin Wu 2 , * , Bin Yu 3 , Kang Li Liu 3 , Guang Xiong Zhou 3 , Guo Qiang Qian 3 , Da Hong Ju 4 , Xiao Yin Chen 5 , **

AUTHORS INFORMATION

1 Department of Gastroenterology, the Peoples Hospital of Heshan, China

2 Department of Traditional Chinese Medicine, Medicine College of Jinan University, China

3 Department of Traditional Chinese Medicine, Medicine College of Jinan University, China

4 Institute of Basic Theories of Traditional Chinese Medicine, China Academy of Traditional Chinese Medicine, China

5 Department of Traditional Chinese Medicine, Medicine College of Jinan University, tchenxiaoyin@jnu.edu.cn, China

Corresponding Authors:

How to Cite: He H, Wu X, Yu B, Liu K, Zhou G, et al. The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15, Hepat Mon. Online ahead of Print ; 11(5):364-367.

ARTICLE INFORMATION

Hepatitis Monthly: 11 (5); 364-367
Article Type: Research Article
Received: August 29, 2010
Accepted: December 4, 2010

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Previous studies suggest that annonaceous may cause permeability glycoprotein (P-gp) function to abate, leading to cell apoptosis. It has also been reported that annonaceous acetogenins affect hepatocellular carcinoma (HCC) cells in the G1 phase, leading to apoptosis. Desacetyluvaricin (Des), a new type of annonaceous acetogenin monomer, has a significant effect on HCC, with few side effects.
Objectives: To investigate the effect of Des on the expression of Toll-like receptor 4 (TLR4) and P53 protein in HCC.
Materials and Methods: HCC HepG2.2.15 cell was cultured by routine method. HepG2.2.15 cells were divided into three groups: control group, treated with Des and DDP (cisplatin) which were examined by immunofluorescence flow cytometry for expression of TLR4 and P53.
Results: TLR4 was expressed by more cells in the Des group than in the cisplatin or serum-only groups (71.94%, 42.64%, and 37.16%, respectively; Des vs.cisplatin: p < 0.05; Des vs. serum only: p < 0.05), with no difference between the cisplatin and serum-only groups (p > 0.05). P53 was expressed by more cells in the Des and cisplatin groups than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and cisplatin groups (p > 0.05).
Conclusions: Des increases TLR4 and P53 expression in HCC cells. Improved immune recognition by the former effect and induction of apoptosis by the latter could be the mechanisms of Des's clinical effects on HCC.
Keywords: Desacetyluvaricin; TLR4 receptor; P53 tumor suppressor protein; Flow cytometry; Hepatocellular carcinoma


  • Implication for health policy/practice/research/medical education:
    Finding new molecular methods for diagnosis and treating HCC has highly degree of attention when other researchers try to follow and complete a unique strategy. Reading this article is recommended to oncologists, hepatologists and molecular genticians.
  • Please cite this paper as:
    He HB, Wu XL, Yu B, Liu KL, Zhou GX, Qian GQ, et al. The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg2.2.15. Hepat Mon.2011;11(5):364-367.

2011 Kowsar M.P.Co. All rights reserved.


Keywords

Desacetyluvaricin TLR4 receptor P53 tumor suppressor protein Flow cytometry Hepatocellular carcinoma

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: